Re: [MOL] Multiple myloma information/REPLY! [01407] Medicine On Line


[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

Re: [MOL] Multiple myloma information/REPLY!




Welcome to our forum, that is now yours to use as much as you care to.  Ask
questions, vent, you name it, we are all here to help you on the journey.
Your friend, lillian

http://intouch.cancernetwork.com/handbook/Myeloma.htm

Multiple Myeloma
Multiple myeloma is a malignant proliferation of plasma cells. The tumor,
its products, and the host response to it result in a number of organ
dysfunctions and symptoms of bone pain or fracture, renal failure,
susceptibility to infection, anemia, hypercalcemia, and

Etiology The cause of myeloma is not known. Myeloma occurred with increased
frequency in those exposed to the radiation of nuclear multiple myeloma,
mieloma, myloma

Incidence And Prevalence About 14,400 cases of myeloma were diagnosed in
1996, and 10,400 people died from the disease. Myeloma increases in
incidence with age. The median age at diagnosis is 68 years. It is rare
under age 40. The yearly incidence is around 4 per 100,000 and

Pathogenesis And Clinical Manifestations Bone pain is the most common
symptom in myeloma, affecting nearly 70 percent of patients. The pain
usually involves the back and ribs, and unlike the pain of metastatic
carcinoma, which often is worse at night, the pain of myeloma is
precipitated by

The next most common clinical problem in patients with myeloma is
susceptibility to bacterial infections. The most common infections are
pneumonias and pyelonephritis, and the most frequent pathogens are
Streptococcus pneumoniae, Staphylococcus aureus, and Klebsiella pneumoniae
in the lungs and Escherichia coli and other gram-negative organisms in the
urinary tract. In about 25 percent of patients, recurrent infections are
multiple myeloma, mieloma, myloma, myaloma

Renal failure occurs in nearly 25 percent of myeloma patients, and some
renal pathology is noted in over half. There are many contributing factors.
Hypercalcemia is the most common cause of renal failure. Glomerular deposits
of amyloid, hyperuricemia, recurrent infections, and

Anemia occurs in about 80 percent of myeloma patients. It is usually
normocytic and normochromic and related both to the replacement of normal
marrow by expanding tumor cells and to the inhibition of hematopoiesis by
factors made by the tumor. In addition, mild hemolysis may contribute to the
anemia. A larger than

TREATMENT

About 10 percent of patients with myeloma will have an indolent course
demonstrating only very slow progression of disease over many years. Such
patients only require antitumor therapy when the serum myeloma protein level
rises above 50 g/L (5 g/dL) or progressive bone lesions develop. Patients
with

The vast majority of patients with myeloma require therapeutic intervention.
In general, such therapy is of two sorts: systemic chemotherapy to control
the progression of myeloma, and symptomatic supportive care to prevent
serious morbidity from the complications of the disease. All patients with
stage II or III disease and stage I patients exhibiting Bence Jones
proteinuria, progressive lytic bone lesions, vertebral compression
fractures, recurrent infections, or

The standard treatment has consisted of intermittent pulses of an alkylating
agent [L-phenylalanine mustard (L-PAM, melphalan), cyclophosphamide, or
chlorambucil] and prednisone administered for 4 to 7 days every 4 to 6
weeks. The alkylating agents appear to be roughly equally active, but
resistance to one agent is often accompanied by resistance to Melphalan is
used most commonly, but because of their near equivalence in antitumor
efficacy, we favor cyclophosphamide as

The ideal duration of therapy has not been determined. Most physicians treat
every 4 to 6 weeks for 1 or 2 years. Cessation of therapy is followed by
relapse, usually within a year. Retreatment may be associated with a second
response in up to 80 percent of patients. Maintenance therapy (e.g., with
IFNa) may prolong the duration of response, but this therapy is toxic and
has generally not prolonged survival. The regrowth rate of the tumor during
relapse accelerates with each relapse. This observation suggests that


Warmly, lillian

Welcome to our forum, that is now your's to use as much as you care to.  Ask
questions, vent, you name it, we are all here to help you on the journey.
Your friend, lillian

http://intouch.cancernetwork.com/handbook/Myeloma.htm

Multiple Myeloma
Multiple myeloma is a malignant proliferation of plasma cells. The tumor,
its products, and the host response to it result in a number of organ
dysfunctions and symptoms of bone pain or fracture, renal failure,
susceptibility to infection, anemia, hypercalcemia, and

Etiology The cause of myeloma is not known. Myeloma occurred with increased
frequency in those exposed to the radiation of nuclear multiple myeloma,
mieloma, myloma

Incidence And Prevalence About 14,400 cases of myeloma were diagnosed in
1996, and 10,400 people died from the disease. Myeloma increases in
incidence with age. The median age at diagnosis is 68 years. It is rare
under age 40. The yearly incidence is around 4 per 100,000 and

Pathogenesis And Clinical Manifestations Bone pain is the most common
symptom in myeloma, affecting nearly 70 percent of patients. The pain
usually involves the back and ribs, and unlike the pain of metastatic
carcinoma, which often is worse at night, the pain of myeloma is
precipitated by

The next most common clinical problem in patients with myeloma is
susceptibility to bacterial infections. The most common infections are
pneumonias and pyelonephritis, and the most frequent pathogens are
Streptococcus pneumoniae, Staphylococcus aureus, and Klebsiella pneumoniae
in the lungs and Escherichia coli and other gram-negative organisms in the
urinary tract. In about 25 percent of patients, recurrent infections are
multiple myeloma, mieloma, myloma, myaloma

Renal failure occurs in nearly 25 percent of myeloma patients, and some
renal pathology is noted in over half. There are many contributing factors.
Hypercalcemia is the most common cause of renal failure. Glomerular deposits
of amyloid, hyperuricemia, recurrent infections, and

Anemia occurs in about 80 percent of myeloma patients. It is usually
normocytic and normochromic and related both to the replacement of normal
marrow by expanding tumor cells and to the inhibition of hematopoiesis by
factors made by the tumor. In addition, mild hemolysis may contribute to the
anemia. A larger than

TREATMENT

About 10 percent of patients with myeloma will have an indolent course
demonstrating only very slow progression of disease over many years. Such
patients only require antitumor therapy when the serum myeloma protein level
rises above 50 g/L (5 g/dL) or progressive bone lesions develop. Patients
with

The vast majority of patients with myeloma require therapeutic intervention.
In general, such therapy is of two sorts: systemic chemotherapy to control
the progression of myeloma, and symptomatic supportive care to prevent
serious morbidity from the complications of the disease. All patients with
stage II or III disease and stage I patients exhibiting Bence Jones
proteinuria, progressive lytic bone lesions, vertebral compression
fractures, recurrent infections, or

The standard treatment has consisted of intermittent pulses of an alkylating
agent [L-phenylalanine mustard (L-PAM, melphalan), cyclophosphamide, or
chlorambucil] and prednisone administered for 4 to 7 days every 4 to 6
weeks. The alkylating agents appear to be roughly equally active, but
resistance to one agent is often accompanied by resistance to Melphalan is
used most commonly, but because of their near equivalence in antitumor
efficacy, we favor cyclophosphamide as

The ideal duration of therapy has not been determined. Most physicians treat
every 4 to 6 weeks for 1 or 2 years. Cessation of therapy is followed by
relapse, usually within a year. Retreatment may be associated with a second
response in up to 80 percent of patients. Maintenance therapy (e.g., with
IFNa) may prolong the duration of response, but this therapy is toxic and
has generally not prolonged survival. The regrowth rate of the tumor during
relapse accelerates with each relapse. This observation suggests that


Warmly, lillian

 
 
We invite you to take a look at our Album.                                               
www.angelfire.com/sc/molangels/index.html
 
  ( Very informational, good tips, Molers pictures, art work and much more....
----- Original Message -----
From: lisafix
To: mol-cancer@lists.meds.com
Sent: Tuesday, August 15, 2000 12:27 PM
Subject: Re: [MOL] Multiple myloma information

Lillian,

  Help, this is your area. I am not the URL whiz kid. Could you drop Monica a few in the right direction?  Lisa

The Curds wrote:

 Lisa,Could you forward me any information you have on multiple myloma?  My grandmother was just diagnosed with it, and we are trying to find out more about it. Thanks,Monica